Skip to content

Cryoablation as a Minimally Invasive Alternative to Surgery for Managing Ductal Carcinoma In Situ

Cryoablation as a Minimally Invasive Alternative to Surgery for Managing Ductal Carcinoma In Situ

Status
Recruiting
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT05218044
Acronym
DCIS
Enrollment
30
Registered
2022-02-01
Start date
2021-11-01
Completion date
2026-11-01
Last updated
2023-03-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Ductal Carcinoma in Situ

Keywords

DCIS

Brief summary

Cryoablation or tumor freezing is a percutaneous, office-based procedure that is emerging as a minimally invasive, cost-effective alternative to surgery that is currently being evaluated in clinical trials for the management of for early-stage invasive breast cancer. The investigator will also evaluate the potential of cryoablation as a minimally invasive alternative to surgery for small areas of DCIS by examining its ability to achieve complete ablation of DCIS within the targeted cryoablation zone of necrosis.

Interventions

PROCEDURECryoablation

The cryoprobe tip will be inserted into the breast and directed under ultrasound guidance to the location where the ultrasound visible marker is located. Next, the cryoprobe will be used to freeze a 4 X 3 X 3 cm diameter area of DCIS using two separate 10-minute freeze cycles separated by a single 10-minute thaw cycle. The cryoprobe will remain in place the entire time. After the second freeze, the cryoprobe will be withdrawn from the breast and a bandage will be applied to the skin.

Sponsors

Helen Rey Breast Cancer Research Foundation
CollaboratorUNKNOWN
California Oncology Research Institute
CollaboratorUNKNOWN
Doterra Healing Hands Foundation
CollaboratorUNKNOWN
Glendale Adventist Medical Center d/b/a Adventist Health Glendale
Lead SponsorOTHER

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
FEMALE
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* DCIS spanning 2 cm or less based on its radiographic appearance by mammography and/or breast contrast-enhanced MRI * Diagnosis of DCIS by minimally invasive needle biopsy * No prior history of DCIS or invasive breast cancer in the same breast * No history of surgical biopsy and/or lumpectomy for diagnosis/treatment in the same breast * Adequate breast volume and skin clearance to permit cryoablation as assessed by Dr. Holmes. This excludes male and females with breasts too small to allow safe cryoablation * Non-pregnant, non-lactating, and no history of pregnancy within the preceding 6 months * No history of breast radiation in the same breast

Design outcomes

Primary

MeasureTime frameDescription
Ability of cryoablation to achieve complete ablation of DCIS6 monthsNumber of participants to achieve completeness of ablation by measuring the percentage of subjects with no residual DCIS or invasive cancer within the zero of necrosis assessed in the post-cryoablation core biopsy obtained 6 months post-cryoablation.

Secondary

MeasureTime frameDescription
Recurrence rate5 yearsNumber of participants at the 5-year rate of invasive breast cancer recurrence after cryoablation of DCIS measuring \</= 2cm.

Countries

United States

Contacts

Primary ContactDennis R Holmes, M.D.
drholmesmd50@gmail.com800-203-5515

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026